Acutaas Chemicals Ltd
NSE:ACUTAAS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 086.4
1 872.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Acutaas Chemicals Ltd
Net Income (Common)
Acutaas Chemicals Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Acutaas Chemicals Ltd
NSE:ACUTAAS
|
Net Income (Common)
₹1.6B
|
CAGR 3-Years
30%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹57.7B
|
CAGR 3-Years
23%
|
CAGR 5-Years
29%
|
CAGR 10-Years
15%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹54.4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
12%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹104.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
48%
|
CAGR 10-Years
14%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Net Income (Common)
₹43.2B
|
CAGR 3-Years
299%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹21.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
Acutaas Chemicals Ltd
Glance View
Acutaas Chemicals Ltd. engages in the development and commercialization of pharmaceutical intermediate products and specialty chemicals. The company is headquartered in Surat, Gujarat. The company went IPO on 2021-09-14. The company is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. The company manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. The company has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.
See Also
What is Acutaas Chemicals Ltd's Net Income (Common)?
Net Income (Common)
1.6B
INR
Based on the financial report for Mar 31, 2025, Acutaas Chemicals Ltd's Net Income (Common) amounts to 1.6B INR.
What is Acutaas Chemicals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
42%
Over the last year, the Net Income (Common) growth was 271%. The average annual Net Income (Common) growth rates for Acutaas Chemicals Ltd have been 30% over the past three years , 42% over the past five years .